- Trials with a EudraCT protocol (12)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
12 result(s) found for: Molecular weight cut off.
Displaying page 1 of 1.
EudraCT Number: 2006-004495-13 | Sponsor Protocol Number: BAY 59-7939/11702 | Start Date*: 2007-03-12 |
Sponsor Name:Bayer Healthcare AG | ||
Full Title: Oral direct factor Xa inhibitor rivaroxaban in patients with acute symptomatic deep-vein thrombosis or pulmonary embolism. | ||
Medical condition: Treatment and secondary prevention of venous thromboembolism in patients with acute symptomatic deep- vein thrombosis or pulmonary embolism | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: BE (Completed) ES (Completed) SE (Completed) FR (Completed) DE (Completed) FI (Completed) DK (Completed) HU (Completed) AT (Completed) IT (Completed) GB (Completed) CZ (Completed) NL (Completed) IE (Completed) LT (Completed) EE (Completed) LV (Completed) SK (Completed) | ||
Trial results: View results |
EudraCT Number: 2016-000133-40 | Sponsor Protocol Number: 2016-2369 | Start Date*: 2016-05-25 |
Sponsor Name:Gustave Roussy | ||
Full Title: European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors | ||
Medical condition: Relapsed or refractory tumors in children | ||
Disease: | ||
Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: FR (Trial now transitioned) ES (Ongoing) NL (Trial now transitioned) GB (GB - no longer in EU/EEA) IT (Trial now transitioned) DK (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2015-001467-39 | Sponsor Protocol Number: GETNE1509 | Start Date*: 2015-07-24 | ||||||||||||||||
Sponsor Name:GETNE (Grupo Español de Tumores Neuroendocrinos) | ||||||||||||||||||
Full Title: A phase II study to evaluate the safety and efficacy of lenvatinib in patients with advanced grade 1/2 neuroendocrine neoplasmas of pancreatic and extrapancreatic origin. | ||||||||||||||||||
Medical condition: Patients with advanced/metastatic, histologically confirmed, grade 1/2 (G1/G2) of 2010 WHO classification neuroendocrine tumors of the pancreas after progression to a previous targeted agent (cohor... | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: ES (Ongoing) AT (Completed) IT (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2004-002171-16 | Sponsor Protocol Number: BAY 59-7939 / 11528 | Start Date*: 2005-01-10 | |||||||||||
Sponsor Name:Bayer HealthCare AG | |||||||||||||
Full Title: Once-daily oral Direct Factor Xa Inhibitor BAY 59-7939 in Patients with acute symptomatic Deep Vein Thrombosis. The Einstein-DVT dose-finding study. | |||||||||||||
Medical condition: Acute syntomatic deep vein thrombosis | |||||||||||||
|
|||||||||||||
Population Age: | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Completed) DK (Completed) CZ (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-010390-21 | Sponsor Protocol Number: ML21965 | Start Date*: 2010-02-10 | |||||||||||
Sponsor Name:Roche Pharma AG | |||||||||||||
Full Title: A randomized, open-label, multi-center Phase II trial of bevacizumab and radiotherapy fol-lowed by bevacizumab and irinotecan vs. temozolomide and radiotherapy followed by temo-zolomide monotherapy... | |||||||||||||
Medical condition: Glioblastoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-004539-39 | Sponsor Protocol Number: TB-402-004 | Start Date*: 2008-12-19 | |||||||||||
Sponsor Name:ThromboGenics N.V | |||||||||||||
Full Title: Single Intravenous Administration of TB-402 for the Prophylaxis of Venous hromboembolic Events (VTE) After Total Knee Replacement Surgery: A Dose-Escalating, Multicenter, Randomised, Active-Control... | |||||||||||||
Medical condition: Venous thrombolic events | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: LV (Completed) BG (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-006044-27 | Sponsor Protocol Number: IFCT-2103 | Start Date*: 2022-02-10 | |||||||||||
Sponsor Name:IFCT | |||||||||||||
Full Title: A phase II-III randomized trial evaluating maintenance pembrolizumab (± pemetrexed) until progression versus observation (± pemetrexed) after 6 months of platinum-based doublet chemotherapy plus pe... | |||||||||||||
Medical condition: Advanced Non Small Cell Lung Cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-012072-28 | Sponsor Protocol Number: MO22468 | Start Date*: 2009-11-23 | |||||||||||
Sponsor Name:F. Hoffmann-La Roche Ltd | |||||||||||||
Full Title: Estudio randomizado en fase IIIb de MabThera® (rituximab) agregado a quimioterápia, bendamustina o clorambucilo, en pacientes con leucemia linfática crónica. A randomized Phase IIIb study of MabTh... | |||||||||||||
Medical condition: Pacientes con leucemia linfática crónica (LLC) en primera linea o segunda línea (máximo de una línea de tratamiento previa) con necesidad de tratamiento. (En España, solo se incluirán pacientes en ... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) SE (Completed) FR (Completed) FI (Completed) PT (Completed) GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-002155-24 | Sponsor Protocol Number: H3E-EW-S124 | Start Date*: 2008-08-06 | ||||||||||||||||
Sponsor Name:Eli Lilly and Company Limited, UK | ||||||||||||||||||
Full Title: A Phase 3, Double-Blind, Placebo-Controlled Study of Maintenance Pemetrexed plus Best Supportive Care versus Best Supportive Care Immediately Following Induction Treatment with Pemetrexed + Cisplat... | ||||||||||||||||||
Medical condition: Advanced Non-Squamous Non Small Cell Lung cancer | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: NL (Completed) GB (Completed) PT (Completed) ES (Completed) DE (Completed) FR (Completed) FI (Completed) BE (Completed) IT (Completed) GR (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2006-001365-42 | Sponsor Protocol Number: BO20231 | Start Date*: 2006-09-27 | |||||||||||
Sponsor Name:F. Hoffmann-La Roche Ltd | |||||||||||||
Full Title: A randomized, open-label, 2-arm, multicentre, phase III study to evaluate the efficacy and safety of bevacizumab in combination with trastuzumab / docetaxel compared with trastuzumab / docetaxel al... | |||||||||||||
Medical condition: First-line treatment of patients with HER2 negative metastatic breast cancer. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Completed) IT (Completed) CZ (Completed) ES (Completed) GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-003974-29 | Sponsor Protocol Number: D6186C00001 | Start Date*: 2019-08-15 | |||||||||||
Sponsor Name:AstraZeneca AB | |||||||||||||
Full Title: A Biomarker-Directed Phase 2 Platform Study in Patients with Advanced Non-Small Cell Lung Cancer whose Disease has Progressed on First-Line Osimertinib Therapy | |||||||||||||
Medical condition: Advanced Non-Small Cell Lung Cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Trial now transitioned) NO (Trial now transitioned) DK (Completed) ES (Ongoing) NL (Trial now transitioned) IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-002990-84 | Sponsor Protocol Number: MOR208C310 | Start Date*: 2021-03-01 | ||||||||||||||||
Sponsor Name:MorphoSys AG | ||||||||||||||||||
Full Title: A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untre... | ||||||||||||||||||
Medical condition: Newly-diagnosed high-intermediate and high-risk diffuse large B-cell lymphoma (DLBCL). | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: FR (Trial now transitioned) IE (Trial now transitioned) DE (Trial now transitioned) CZ (Trial now transitioned) SK (Trial now transitioned) HU (Trial now transitioned) AT (Trial now transitioned) IT (Trial now transitioned) RO (Trial now transitioned) | ||||||||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
• EEA CTAs: Date study was authorised to proceed
• Outside EU/EEA: Date study was submitted in EudraCT
• Outside EU/EEA: Date study was submitted in EudraCT
